Recent advances in immunotherapy and combination therapies are revolutionizing the treatment landscape for both metastatic ...

Gilead’s Trodelvy has another string to its bow after FDA approval in patients with advanced metastatic urothelial cancer. Trodelvy (sacituzumab govitecan) has been approved for locally ...

Distant metastasis-free survival: the time which cancer does not spread to distant organs ... provide additional support for ...

TYRA-300 showed promising safety and preliminary antitumor activity in FGFR3-altered metastatic urothelial cancer, with a 54.5% partial response rate and 100% disease control in the SURF301 trial.

Therefore future research should also try to assess whether class I HDACs have a prognostic value in locally advanced invasive or metastatic urothelial cancer.

Anti-tumor activity was observed across all patients with FGFR3-altered metastatic urothelial carcinoma who were treated at the dose levels of 90 mg and higher. TYRA-300, an investigational oral FGFR3 ...

1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. *Corresponding Author: Michael H. Brave, Center for Drug Evaluation and Research, U.S. Food and ...

The issue to discuss here is if the metastasis should have been resected ... However, over 50% of patients with urothelial cancer are 'unfit' (a GFR less than 60 mL/min and/or a performance ...

November 4, 2024 Modulation of the tumor microenvironment in non-muscle-invasive bladder cancer by OncoTherad® (MRB-CFI-1) nanoimmunotherapy: effects on tumor-associated macrophages, ...